PLA2G7 gene polymorphisms and coronary heart disease risk: A meta-analysis

Thrombosis Research

Volumn 126, Issue 6, 2010, Pages 498-503

  Wang, Qianqian ^a   Hao, Yongchen ^a   Mo, Xingbo ^a   Wang, Laiyuan ^a   Lu, Xiangfeng ^a   Huang, Jianfeng ^a   Cao, Jie ^a   Li, Hongfan ^a   Gu, Dongfeng ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

Coronary heart disease; Meta analysis; PLA2G7; Polymorphism

Indexed keywords

PROTEIN PLA2G7; THROMBOCYTE ACTIVATING FACTOR; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; EMBASE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MEDLINE; PHENOTYPE; PRIORITY JOURNAL; SYSTEMATIC REVIEW;

CORONARY DISEASE; HUMANS; PHOSPHOLIPASES A2; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 78649742267     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2010.09.009     Document Type: Article

References (45)

1. C.J. Packard, D.S. O'Reilly, M.J. Caslake, A.D. McMahon, I. Ford, and J. Cooney Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group N Engl J Med 343 2000 1148 1155
2. W. Koenig, N. Khuseyinova, H. Lowel, G. Trischler, and C. Meisinger Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany Circulation 110 2004 1903 1908
3. H.T. May, B.D. Horne, J.L. Anderson, R.L. Wolfert, J.B. Muhlestein, and D.G. Renlund Lipoprotein-associated phospholipase A2 independently predicts the angiographic diagnosis of coronary artery disease and coronary death Am Heart J 152 2006 997 1003
4. W. Koenig, D. Twardella, H. Brenner, and D. Rothenbacher Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress Arterioscler Thromb Vasc Biol 26 2006 1586 1593
5. H.H. Oei, I.M. van der Meer, A. Hofman, P.J. Koudstaal, T. Stijnen, and M.M. Breteler Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study Circulation 111 2005 570 575
6. E.S. Brilakis, J.P. McConnell, R.J. Lennon, A.A. Elesber, J.G. Meyer, and P.B. Berger Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up Eur Heart J 26 2005 137 144
7. C.M. Ballantyne, R.C. Hoogeveen, H. Bang, J. Coresh, A.R. Folsom, and G. Heiss Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study Circulation 109 2004 837 842
8. K. Winkler, B.R. Winkelmann, H. Scharnagl, M.M. Hoffmann, A.B. Grawitz, and M. Nauck Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study Circulation 111 2005 980 987
9. C.A. Garza, V.M. Montori, J.P. McConnell, V.K. Somers, I.J. Kullo, and F. Lopez-Jimenez Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review Mayo Clin Proc 82 2007 159 165
10. W. Koenig, and N. Khuseyinova Lipoprotein-associated and secretory phospholipase A2 in cardiovascular disease: the epidemiological evidence Cardiovasc Drugs Ther 23 2009 85 92
11. R.S. Rosenson, C. Hislop, D. McConnell, M. Elliott, Y. Stasiv, and N. Wang Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial Lancet 373 2009 649 658
12. E.R. Mohler III, C.M. Ballantyne, M.H. Davidson, M. Hanefeld, L.M. Ruilope, and J.L. Johnson The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study J Am Coll Cardiol 51 2008 1632 1641
13. G. Theilmeier, B. De Geest, P.P. Van Veldhoven, D. Stengel, C. Michiels, and M. Lox HDL-associated PAF-AH reduces endothelial adhesiveness in apoE-/- mice FASEB J 14 2000 2032 2039
14. R. Quarck, B. De Geest, D. Stengel, A. Mertens, M. Lox, and G. Theilmeier Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice Circulation 103 2001 2495 2500
15. T. Hakkinen, J.S. Luoma, M.O. Hiltunen, C.H. Macphee, K.J. Milliner, and L. Patel Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions Arterioscler Thromb Vasc Biol 19 1999 2909 2917
16. Y. Yamada, S. Ichihara, T. Fujimura, and M. Yokota Identification of the G994- > T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men Metab, Clin Exp 47 1998 177 181
17. A.M. Abuzeid, E. Hawe, S.E. Humphries, and P.J. Talmud Association between the Ala379Val variant of the lipoprotein associated phospholipase A2 and risk of myocardial infarction in the north and south of Europe Atherosclerosis 168 2003 283 288
18. E. Ninio, D. Tregouet, J.L. Carrier, D. Stengel, C. Bickel, and C. Perret Platelet-activating factor-acetylhydrolase and PAF-receptor gene haplotypes in relation to future cardiovascular event in patients with coronary artery disease Hum Mol Genet 13 2004 1341 1351
19. T. Ito, H. Yasue, M. Yoshimura, S. Nakamura, M. Nakayama, and Y. Shimasaki Paraoxonase gene Gln192Arg (Q192R) polymorphism is associated with coronary artery spasm Hum Genet 110 2002 89 94
20. P.Y. Liu, H.C. Chung, J.Y. Chen, C.H. Lee, S.H. Chan, and Y.H. Li Platelet-activating factor-acetylhydrolase (PLA2G7) A379V (exon 11) gene polymorphism is functionally associated with coronary artery disease severity but not the onset of acute coronary syndrome Acta Cardiol Sin 22 2006 212 220
21. S.J. Chanock, T. Manolio, M. Boehnke, E. Boerwinkle, D.J. Hunter, and G. Thomas Replicating genotype-phenotype associations Nature 447 2007 655 660
22. C. Lluis-Ganella, G. Lucas, I. Subirana, V. Escurriol, M. Tomas, and M. Senti Qualitative assessment of previous evidence and an updated meta-analysis confirms lack of association between the ESR1 rs2234693 (PvuII) variant and coronary heart disease in men and women Atherosclerosis 207 2009 480 486
23. R. DerSimonian, and N. Laird Meta-analysis in clinical trials Control Clin Trials 7 1986 177 188
24. J.P. Higgins, S.G. Thompson, J.J. Deeks, and D.G. Altman Measuring inconsistency in meta-analyses BMJ 327 2003 557 560
25. M. Egger, G. Davey Smith, M. Schneider, and C. Minder Bias in meta-analysis detected by a simple, graphical test BMJ 315 1997 629 634
26. B.S. Sutton, D.R. Crosslin, S.H. Shah, S.C. Nelson, A. Bassil, and A.B. Hale Comprehensive genetic analysis of the platelet activating factor acetylhydrolase (PLA2G7) gene and cardiovascular disease in case-control and family datasets Hum Mol Genet 17 2008 1318 1328
27. M. Xu, J. Sun, G. Luo, J. Bai, Y. Liu, and H. Ke Association between lipoprotein-associated phospholipase A2 gene R92H polymorphism and coronary heart disease in Han Chinese Chin J Arterioscler 16 2008 965 968
28. M. Xu, J. Sun, G. Lou, J. Bai, H. Ke, and Y. Liu Connecting research to lipoprotein-associated phosphofipaseA2 gene polymorphisms of the patients with coronary heart disease J Clin Intern Med 26 2009 18 20
29. Xu M. Connecting Research to LP-PLA2 Gene Polymorphisms R92H and A379V of the Patients with Coronary Heart Disease. Dissertation, Suzhou University, 2009.
30. Y. Yamada, H. Yoshida, S. Ichihara, T. Imaizumi, K. Satoh, and M. Yokota Correlations between plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and PAF-AH genotype, age, and atherosclerosis in a Japanese population Atherosclerosis 150 2000 209 216
31. K. Shimokata, Y. Yamada, T. Kondo, S. Ichihara, H. Izawa, and K. Nagata Association of gene polymorphisms with coronary artery disease in individuals with or without nonfamilial hypercholesterolemia Atherosclerosis 172 2004 167 173 (Pubitemid 38058616)
32. Hou L. Associations of two inflammation genes-PLA2G7 and TNF with coronary heart disease in a Chinese Han population. Dissertation, Peking Union Medical College, 2009.
33. A. Hirashiki, Y. Yamada, Y. Murase, Y. Suzuki, H. Kataoka, and Y. Morimoto Association of gene polymorphisms with coronary artery disease in low- or high-risk subjects defined by conventional risk factors J Am Coll Cardiol 42 2003 1429 1437
34. M.M. Hoffmann, K. Winkler, W. Renner, B.R. Winkelmann, U. Seelhorst, and B. Wellnitz Genetic variants and haplotypes of lipoprotein associated phospholipase A2 and their influence on cardiovascular disease (The Ludwigshafen Risk and Cardiovascular Health Study) J Thromb Haemost 7 2009 41 48
35. L. Hou, S. Chen, H. Yu, X. Lu, J. Chen, and L. Wang Associations of PLA2G7 gene polymorphisms with plasma lipoprotein-associated phospholipase A2 activity and coronary heart disease in a Chinese Han population: The Beijing atherosclerosis study Hum Genet 125 2009 11 20
36. P.Y. Liu, Y.H. Li, H.L. Wu, T.H. Chao, L.M. Tsai, and L.J. Lin Platelet-activating factor-acetylhydrolase A379V (exon 11) gene polymorphism is an independent and functional risk factor for premature myocardial infarction J Thromb Haemost 4 2006 1023 1028
37. J. Mashiba, G. Koike, H. Kamiunten, M. Ikeda, and K. Sunagawa Vasospastic angina and microvascular angina are differentially influenced by PON1 A632G polymorphism in the Japanese Circ J 69 2005 1466 1471
38. C. Sekuri, F.S. Cam, I. Tengiz, E. Ercan, O. Bayturan, and A. Berdeli Association of platelet-activating factor acetylhydrolase gene polymorphism with premature coronary artery disease in Turkish patients Anadolu Kardiyol Derg 6 2006 132 134
39. Li L. Association of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Gene and Coronary heart disease. Dissertation, Peking Union Medical College, 2008.
40. H. Zhang, F. Sun, S. Wang, Q. He, F. Ji, and F. Xu Associationg between gegetic variation in PAF-AH V279F and coronary heart disease Chin J Geriatr 25 2006 895 899
41. S. Hohda, A. Kimura, T. Sasaoka, T. Hayashi, K. Ueda, and M. Yasunami Association study of CD14 polymorphism with myocardial infarction in a Japanese population Jpn Heart J 44 2003 613 622
42. Y. Jang, O.Y. Kim, S.J. Koh, J.S. Chae, Y.G. Ko, and J.Y. Kim The Val279Phe variant of the lipoprotein-associated phospholipase A2 gene is associated with catalytic activities and cardiovascular disease in Korean men J Clin Endocrinol Metab 91 2006 3521 3527
43. S. Kruse, X.Q. Mao, A. Heinzmann, S. Blattmann, M.H. Roberts, and S. Braun The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma Am J Hum Genet 66 2000 1522 1530
44. A.K. Daly, and C.P. Day Candidate gene case-control association studies: advantages and potential pitfalls Br J Clin Pharmacol 52 2001 489 499
45. J.P. Ioannidis, P. Boffetta, J. Little, T.R. O'Brien, A.G. Uitterlinden, and P. Vineis Assessment of cumulative evidence on genetic associations: interim guidelines Int J Epidemiol 37 2008 120 132